ONCOLOGY: Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML

Audio Journal of Oncology, December 9th, 2007 Reporting from: American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML RICHARD STONE, Dana-Farber Cancer Institute, Boston GEORGE CANELLOS, Dana-Farber Cancer Institute, Boston REFERENCE: ABSTRACT 734, ASH 2007 New data shows that dasatinib is giving durable responses in patients with chronic phase chronic myeloid leukemia who have failed, or who cannot tolerate imatinib. So where does dasatinib stand as an emerging CML therapy? Richard Stone of the Dana-Farber Cancer Institute in Boston explained all to Derek Thorne, while George Canellos, of the same institute, gave another perspective on the data.

You can listen to ONCOLOGY: Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML online on Radio and Podcast. Open the player on this page to stream the available audio.

ONCOLOGY: Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML is an episode from Audio Medica News - Medical News Interviews by Audio Medica.

This episode is 00:04:32 long.

This episode was published on Dec 10, 2007.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Audio Medica News - Medical News Interviews when more episodes are available from the podcast feed.